# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confide...
Oppenheimer analyst Francois Brisebois upgrades Aldeyra Therapeutics (NASDAQ:ALDX) from Perform to Outperform and announces ...
HC Wainwright & Co. analyst Matthew Caufield reinstates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and announces $10 ...
Based on positive biomarker results observed in adult cohort of Phase 2 clinical trial of ADX-629 in Sjögren-Larsson Syndrome, ...
As a result of the Exercise Period Extension, AbbVie may exercise the Option by delivering written notice to Aldeyra at any tim...
Aldeyra Therapeutics Inc (NASDAQ: ALDX) released topline results from a Phase 2 clinical trial of ADX-629, an investigational R...